Navigation Links
Beckman Coulter's 4th Quarter and Full Year 2007 Revenue Grows 10.8% and 9.2%, Respectively; 2007 Earnings Per Share Beat Outlook
Date:2/8/2008

(1.4) 12.5

Long-term lease receivables 14.0 46.6

Other (24.0) (7.0)

Net cash provided by operating

activities of continuing operations 401.0 304.4

Net cash used in operating activities

of Discontinued operations (1.0) (21.6)

Net cash provided by operating

activities 400.0 282.8

Cash flows from investing activities

Additions to property, plant and equipment (277.3) (276.3)

Proceeds from sale of land 30.9 -

Sale of marketable securities 17.7 -

Payments for business acquisitions and

technology

Licenses, net of cash acquired (118.2) (194.6)

Net cash used in investing activities

of continuing operations (346.9) (470.9)

Net cash provided by investing

activities of discontinued operations 2.6 50.2

Net cash used in investing activities (344.3) (420.7)

Cash flows from financing activities

Dividends to stockholders (40.4) (37.7)

Distribution to minority (14.2) -

Proceeds from issuance of stock 88.0 54.0

Repurchase of common stock as treasury stock (57.3) (188.4)

Repurchase of common stock held in grantor

trust (1.0) (1.1)

Excess tax benefits from share-based payment

transactions 20.7 7.9

Tax benefit on distribution of stock 1.2
'/>"/>

SOURCE Beckman Coulter, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29

Related medicine news :

1. Beckman Coulter Announces Licensing Option Agreements for Cancer Genes with Johns Hopkins University
2. Beckman Coulter Signs Agreements With Amerinet, Inc.; Ten-Year Partnership Extended for Another Three Years
3. Beckman Coulter to Present at the Credit Suisse Global Healthcare Conference
4. Beckman Coulter to Acquire Flow Cytometry Instrumentation Business From Dako
5. Beckman Coulter to Present at the 2007 RBC Capital Markets Healthcare Conference
6. Haemacure Reports Third Quarter 2007 Results
7. Weight Watchers Declares Quarterly Dividend
8. Memry Corporation Announces Fiscal Fourth Quarter and 2007 Year End Earnings Release and Conference Call
9. Somanetics Corporation to Release Third Quarter 2007 Financial Results and Host Conference Call September 19
10. Medical Services International Maintains Pace in Second Quarter
11. Martek Announces Third Quarter 2007 Financial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/23/2014)... The report, “Market Snapshot: Aesthetic Lasers ... Asia-Pacific” provides quantitative analysis of the three aesthetic ... body contouring devices, non-invasive body contouring devices and ... data by revenue and volume over the 2006 ... South Korea, Australia and India. It uses data ...
(Date:11/23/2014)... Pro Ace Care, a renowned Vancouver hot water ... providing an 8 year warranty on its selected hot water ... up due to the impending winter season, it was important ... premium service that the company provides. As a result, Pro ... Wood and Bradford hot water tanks. , “Every installer ...
(Date:11/23/2014)... friends have more influence on teens, alcohol use than ... "We,ve known for a long time that ... use, but there are no common studies that distinguished ... influence on those decisions," Jonathon Beckmeyer, an assistant professor ... a university news release. Beckmeyer analyzed data gathered ...
(Date:11/23/2014)... a notable magnetic locks maker, has released a variety ... available at low rates up to 30% off. ... emergency doors. The emergency door adopts fireproof material and ... colors. All of the products are top-quality guaranteed. ... as easy as many people think. As a ...
(Date:11/23/2014)... November 23, 2014 To show thanks to ... new collection of white evening dresses for weddings. ... workers 24/7. , iFitDress.com is a distinguished dress manufacturer, and ... supported by worldwide customers for a very long time. The ... where a customer will be able to buy not only ...
Breaking Medicine News(10 mins):Health News:Aesthetic Lasers and Energy Devices Market in APAC (China, Japan, South Korea, Australia and India) to 2020 2Health News:Aesthetic Lasers and Energy Devices Market in APAC (China, Japan, South Korea, Australia and India) to 2020 3Health News:Aesthetic Lasers and Energy Devices Market in APAC (China, Japan, South Korea, Australia and India) to 2020 4Health News:Pro Ace Care Now Gives 8 Year Guarantee on Selected Vancouver Hot Water Tanks 2Health News:Close Friends May Be Key to Teens' Drinking 2Health News:iFitDress.com: Wonderful White Evening Dresses Now Available 2
... Japan, May 30 Stronger health,systems, improved maternal and ... diseases are essential to African development,more than 40 heads ... highlighted in the action plan adopted at,the close of ... countries,were represented, along with many international organizations., Under ...
... sexual appetite. But stimulating new research in the Journal ... eye. A recent study shows that men who watched ... they were making decisions about money, soda, and candy. ... Luk Warlop (KULeuven, Belgium) found that the desire for ...
... study says , , FRIDAY, May 30 (HealthDay News) -- Repetitive ... the spine enough to result in a temporary loss of ... Previous research has suggested that gravity-related compression of the spine ... percent of their height in a normal day. Fortunately, this ...
... patients assume infertility is female issue, though almost half, infertility cases due ... ... factors, PURCHASE, N.Y., May 30 ... female condition, according,to an informal web survey conducted by IntegraMed, the leading ...
... 2008] Golf can be a good investment for the health, ... Karolinska Institutet. The death rate for golfers is 40 per ... age and socioeconomic status, which correspond to a 5 year ... the safest. , It is a well-known fact that ...
... 29, 2008) -- Physician-scientists from NewYork-Presbyterian Hospital/Columbia University ... at the American Society of Clinical Oncology Annual ... Among the most significant presentations are the following: ... Patients With Unresectable Metastatic Melanoma , Dr. Howard ...
Cached Medicine News:Health News:Stronger Health Systems and Better Maternal Health Critical to African Development, Japan Summit Affirms 2Health News:Stronger Health Systems and Better Maternal Health Critical to African Development, Japan Summit Affirms 3Health News:Football Can Shrink Players 2Health News:Fertility Specialists Decry Men's Reluctance to Seek Infertility Treatment 2Health News:Fertility Specialists Decry Men's Reluctance to Seek Infertility Treatment 3Health News:Golf prolongs life 2Health News:NYP/Columbia physician-scientists present at ASCO 44th annual meeting 2Health News:NYP/Columbia physician-scientists present at ASCO 44th annual meeting 3Health News:NYP/Columbia physician-scientists present at ASCO 44th annual meeting 4
(Date:11/24/2014)... SOUTH SAN FRANCISCO, Calif. , Nov. 24, 2014 /PRNewswire/ ... James M. Gower is retiring from the board ... executive officer, and Raul Rodriguez , most recently serving ... the position of chief executive officer and join the board ... Board of Directors since 2005, will become chairman. Mr. Gower ...
(Date:11/24/2014)... , Nov. 24, 2014  Inovio Pharmaceuticals, Inc. (NASDAQ: ... Joseph Kim , President and CEO of Inovio Pharmaceuticals, will ... team to ring the Nasdaq Opening Bell tomorrow, Tuesday November ... September 15 th listing on the Nasdaq Global Select ... Dr. Kim said, "We are honored to ring the Nasdaq ...
(Date:11/22/2014)...  Sprout Pharmaceuticals today announced positive preliminary results from a ... flibanserin up to 200 mg at bedtime had no next-day ... 20 th Annual Fall Scientific Meeting of the Sexual ... Miami . The Phase 1 ... Letter and the Formal Dispute Resolution that was filed in ...
Breaking Medicine Technology:Rigel Announces Executive Management Changes 2Rigel Announces Executive Management Changes 3Inovio Pharmaceuticals to Ring Opening Bell Nov 25th on the Nasdaq Stock Market 2Inovio Pharmaceuticals to Ring Opening Bell Nov 25th on the Nasdaq Stock Market 3Sprout Pharmaceuticals Presents Phase 1 Clinical Trial Data Showing Treatment With Flibanserin Results In No Next-Day Driving Impairment 2Sprout Pharmaceuticals Presents Phase 1 Clinical Trial Data Showing Treatment With Flibanserin Results In No Next-Day Driving Impairment 3
... Regeneron Pharmaceuticals, Inc. (Nasdaq: REGN ) today ... 2) in gout patients initiating allopurinol therapy, ARCALYST (rilonacept) ... primary endpoint was the number of gout flares per ... ARCALYST at a weekly, self-administered, subcutaneous dose of either ...
... Feb. 28, 2011 Nile Therapeutics, Inc. (Nasdaq: ... development of novel therapeutics for cardiovascular disease, announced plans ... heart failure.  Nile plans to develop cenderitide (formerly CD-NP) ... decompensated heart failure (ADHF) patients continuously for up to ...
Cached Medicine Technology:ARCALYST® (rilonacept) Meets Primary and All Secondary Endpoints in Second Phase 3 Trial for Prevention of Gout Flares in Patients Initiating Uric Acid-Lowering Therapy 2ARCALYST® (rilonacept) Meets Primary and All Secondary Endpoints in Second Phase 3 Trial for Prevention of Gout Flares in Patients Initiating Uric Acid-Lowering Therapy 3ARCALYST® (rilonacept) Meets Primary and All Secondary Endpoints in Second Phase 3 Trial for Prevention of Gout Flares in Patients Initiating Uric Acid-Lowering Therapy 4ARCALYST® (rilonacept) Meets Primary and All Secondary Endpoints in Second Phase 3 Trial for Prevention of Gout Flares in Patients Initiating Uric Acid-Lowering Therapy 5ARCALYST® (rilonacept) Meets Primary and All Secondary Endpoints in Second Phase 3 Trial for Prevention of Gout Flares in Patients Initiating Uric Acid-Lowering Therapy 6ARCALYST® (rilonacept) Meets Primary and All Secondary Endpoints in Second Phase 3 Trial for Prevention of Gout Flares in Patients Initiating Uric Acid-Lowering Therapy 7ARCALYST® (rilonacept) Meets Primary and All Secondary Endpoints in Second Phase 3 Trial for Prevention of Gout Flares in Patients Initiating Uric Acid-Lowering Therapy 8ARCALYST® (rilonacept) Meets Primary and All Secondary Endpoints in Second Phase 3 Trial for Prevention of Gout Flares in Patients Initiating Uric Acid-Lowering Therapy 9ARCALYST® (rilonacept) Meets Primary and All Secondary Endpoints in Second Phase 3 Trial for Prevention of Gout Flares in Patients Initiating Uric Acid-Lowering Therapy 10Nile Therapeutics Announces Plans to Pursue a Post-Acute Indication in Heart Failure 2Nile Therapeutics Announces Plans to Pursue a Post-Acute Indication in Heart Failure 3Nile Therapeutics Announces Plans to Pursue a Post-Acute Indication in Heart Failure 4
The A350 test is used for POC testing in hospital emergency departments, replacing the need to draw blood for alcohol testing. Each hash mark is 0.02% or 20 mg/dL....
... Tests are available in 14 configurations including ... using Microgenics Antibody Technology, the SureStep™ MDMA ... care immunoassay targeted to detect MDMA that ... MDEA but no cross-reactivity to any isomer ...
... Drug Screen Tests are available in 14 ... (Ecstasy). Designed using Microgenics Antibody Technology, the ... point of care immunoassay targeted to detect ... MDA and MDEA but no cross-reactivity to ...
... SureStep™ Drug Screen Tests are available in ... MDMA (Ecstasy). Designed using Microgenics Antibody Technology, ... only point of care immunoassay targeted to ... both MDA and MDEA but no cross-reactivity ...
Medicine Products: